Literature DB >> 25630972

Alternative splicing-regulated protein of hepatitis B virus hacks the TNF-α-stimulated signaling pathways and limits the extent of liver inflammation.

Jonathan G Pol1, Bouchra Lekbaby1, François Redelsperger1, Sofieke Klamer1, Yassmina Mandouri1, James Ahodantin1, Ivan Bieche1, Marine Lefevre1, Philippe Souque1, Pierre Charneau1, Noémie Gadessaud1, Dina Kremsdorf1, Patrick Soussan2.   

Abstract

Hepatitis B splicing-regulated protein (HBSP) of the hepatitis B virus (HBV) was uncovered a few years ago but its function remains unknown. HBSP expression occurs from a spliced viral transcript that increases during the course of liver disease. This study aimed at characterizing the impact of HBSP on cellular signaling pathways in vitro and on liver pathogenesis in transgenic (Tg) mice. By RT-qPCR array, NF-κB-inducible genes appeared modulated in HepG2 cells transduced with a HBSP-encoding lentivirus. Using luciferase and Western blot assays, we observed a decreased activation of the NF-κB pathway in HBSP-expressing cells following TNF-α treatment, as illustrated by lower levels of phosphorylated IκB-α. Meanwhile, the level of phosphorylated JNK increased together with the sensitivity to apoptosis. The contrasting effects on JNK and IκB-α activation upon TNF-α stimulation matched with a modulated maturation of TGF-β-activated kinase 1 (TAK1) kinase, assessed by 2-dimensional SDS-PAGE. Inhibition of the NF-κB pathway by HBSP was confirmed in the liver of HBSP Tg mice and associated with a significant decrease of chemically induced chronic liver inflammation, as assessed by immunohistochemistry. In conclusion, HBSP contributes to limit hepatic inflammation during chronic liver disease and may favor HBV persistence by evading immune response. © FASEB.

Entities:  

Keywords:  HBSP; TAK1; hepadnavirus; liver injury

Mesh:

Substances:

Year:  2015        PMID: 25630972     DOI: 10.1096/fj.14-258715

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  8 in total

1.  Diversity of the nucleic acid forms of circulating HBV in chronically infected patients and its impact on viral cycle.

Authors:  Aurélie Schnuriger; Patrick Soussan; Jules Sotty; Pierre Bablon; Bouchra Lekbaby; Jérémy Augustin; Morgane Girier-Dufournier; Lucas Langlois; Céline Dorival; Fabrice Carrat; Stanislas Pol; Hélène Fontaine; Nazim Sarica; Christine Neuveut; Chantal Housset; Dina Kremdsorf
Journal:  Hepatol Int       Date:  2022-08-04       Impact factor: 9.029

2.  Hepatitis B Spliced Protein (HBSP) Suppresses Fas-Mediated Hepatocyte Apoptosis via Activation of PI3K/Akt Signaling.

Authors:  Shu-Xiang Wu; Wan-Nan Chen; Zhen-Tang Jing; Wei Liu; Xin-Jian Lin; Xu Lin
Journal:  J Virol       Date:  2018-11-12       Impact factor: 5.103

3.  Alternative splicing of hepatitis B virus: A novel virus/host interaction altering liver immunity.

Authors:  Marion Duriez; Yassmina Mandouri; Bouchra Lekbaby; Hualin Wang; Aurélie Schnuriger; Francois Redelsperger; Chiara Ida Guerrera; Marine Lefevre; Veronique Fauveau; James Ahodantin; Ivan Quetier; Cerina Chhuon; Samir Gourari; Alexandre Boissonnas; Upkar Gill; Patrick Kennedy; Nabil Debzi; Delphine Sitterlin; Mala K Maini; Dina Kremsdorf; Patrick Soussan
Journal:  J Hepatol       Date:  2017-06-07       Impact factor: 25.083

4.  Hepatitis B Surface Antigen Suppresses the Activation of Nuclear Factor Kappa B Pathway via Interaction With the TAK1-TAB2 Complex.

Authors:  Feiyan Deng; Gang Xu; Zhikui Cheng; Yu Huang; Caijiao Ma; Chuanjin Luo; Chen Yu; Jun Wang; Xiupeng Xu; Shi Liu; Ying Zhu
Journal:  Front Immunol       Date:  2021-02-25       Impact factor: 7.561

5.  More DNA and RNA of HBV SP1 splice variants are detected in genotypes B and C at low viral replication.

Authors:  Ka-Cheung Luk; Jeffrey Gersch; Barbara J Harris; Vera Holzmayer; Dora Mbanya; Silvia Sauleda; Mary A Rodgers; Gavin Cloherty
Journal:  Sci Rep       Date:  2021-12-13       Impact factor: 4.379

6.  Hepatitis B virus spliced variants are associated with an impaired response to interferon therapy.

Authors:  Jieliang Chen; Min Wu; Fan Wang; Wen Zhang; Wei Wang; Xiaonan Zhang; Jiming Zhang; Yinghui Liu; Yi Liu; Yanling Feng; Ye Zheng; Yunwen Hu; Zhenghong Yuan
Journal:  Sci Rep       Date:  2015-11-20       Impact factor: 4.379

Review 7.  Clinical Implications of Hepatitis B Virus RNA and Covalently Closed Circular DNA in Monitoring Patients with Chronic Hepatitis B Today with a Gaze into the Future: The Field Is Unprepared for a Sterilizing Cure.

Authors:  Anastasiya Kostyusheva; Dmitry Kostyushev; Sergey Brezgin; Elena Volchkova; Vladimir Chulanov
Journal:  Genes (Basel)       Date:  2018-10-05       Impact factor: 4.096

Review 8.  Pathogenicity and virulence of Hepatitis B virus.

Authors:  Yu-Chen Chuang; Kuen-Nan Tsai; Jing-Hsiung James Ou
Journal:  Virulence       Date:  2022-12       Impact factor: 5.882

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.